Share This Post

Drug Combo Wins OK as First Line in Kidney Cancer

WASHINGTON — The combination of ipilimumab (Yervoy) and nivolumab (Opdivo) can be used to treat intermediate- to poor-risk patients with previously untreated renal cell carcinoma, the FDA said Monday.

Read More:

Share This Post

Dena Battle is the President of KCCure. She also serves on the Advisory Board for the Johns Hopkins Sidney Kimmel Cancer Center and as a member of the Patient and Family Advisory Council.

Lost Password


Subscribe for updates!